News & Insights - Tune Therapeutics

December 6, 2023

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

November 13, 2023

Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus

May 22, 2023

Tune Therapeutics Unveils Breakthrough Data Showing
Stable and Durable Epigenetic Regulation in Non-Human Primates

April 10, 2023

Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel

January 17, 2023

Tune Therapeutics Welcomes Noted Industry Leader Dr. John McHutchison to Board of Directors

December 2, 2021

Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases

December 6, 2023

Rhapsody in B: Tune Therapeutics Presents Data for Hepatitis B Epigenetic Silencer

December 6, 2023

CRISPR 2.0: a new wave of gene editors heads for clinical trials

August 1, 2023

Emerson Collective Spins Off to Form New Investment Fund, Yosemite

June 8, 2023

In its first, tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

June 8, 2023

A New Tomato And A Potential New Class Of Medicine Share This Fascinating Technology

May 30, 2023

CRISPR tool slashes bad cholesterol by 56% in monkeys

May 23, 2023

ASGCT 2023: Tessera, Tune, Prime Medicine and more present new preclinical data

May 22, 2023

Epigenetic Editing in Non-Human Primates Presented by Tune at ASGCT

September 5, 2022

Chroma Medicine and Tune Therapeutics: Two companies take up epigenome editing

August 18, 2022

Rise of the dead Cas to edit the epigenome

July 26, 2022

Epigenetic editing: A tunable CRISPR alternative

June 6, 2022

A New Kind of Genome Editing Is Here to Fine-Tune DNA

June 1, 2022

Better than CRISPR? Another way to fix gene problems may be safer and more versatile

December 13, 2021

Matt Kane steered his last biotech to an IPO. He's back with a new startup and $40M

December 3, 2021

Former CEO of Durham biotech launches new startup with $40M backing

December 2, 2021

Tune Therapeutics Launches with Epigenomic Control Platform to Master Gene Networks

December 2, 2021

Tune Therapeutics Debuts with $40 Million to Fine-Tune the Human Genome

December 2, 2021

Tune Therapeutics ups the ‘Tempo’ in epigenetic editing with $40M investment

December 2, 2021

Another epigenome editing startup launches from a pair of the field’s longtime leaders

December 2, 2021

Tune Therapeutics' epigenetic platform resonates with investors as it snags $40M in financing

December 2, 2021

Tune Therapeutics launches with $40M in funding, aims to fine-tune activity of genes in cells

August 2, 2021

Transgenic mice for in vivo epigenome editing with CRISPR-based systems

December 1, 2020

Master Regulators and Cofactors of Human Neuronal Cell Fate Specification Identified by CRISPR Gene Activation Screens

April 23, 2020

Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators

April 15, 2019

Increasing the specificity of CRISPR systems with engineered RNA secondary structures

April 26, 2018

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors

April 3, 2017

CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome

September 1, 2016

Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells

April 11, 2016

Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells

October 26, 2015

Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.

May 29, 2015

Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators

April 6, 2015

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers

July 25, 2013

RNA-guided gene activation by CRISPR-Cas9–based transcription factors.

February 3, 2013

Synergistic and tunable human gene activation by combinations of synthetic transcription factors.

August 18, 2022

Rise of the dead Cas to edit the epigenome

June 13, 2022

Gene therapy targets interneurons to tackle Dravet syndrome

June 1, 2022

Better than CRISPR? Another way to fix gene problems may be safer and more versatile

April 19, 2022

Emory researchers successfully use mRNA to activate genes

April 2, 2021

Harbingers of Things to Come in Gene Therapy

February 5, 2021

School of Medicine faculty, students shine during Duke University Research Week

August 4, 2017

The epigenome editors: How tools such as CRISPR offer new details about epigenetics

June 15, 2016

Command and cure: We don't need to edit genomes to control them

March 15, 2016

Gene Editing Casts a Wide Net

December 2, 2015

Epigenetics: The genome unwrapped

April 7, 2015

CRISPR/Cas9 Edits the Epigenome

March 3, 2014

A Powerful New Way to Edit DNA

Media Inquiries

media@tunetx.com

Human Resources Inquiries

careers@tunetx.com

Partnering Inquiries

partners@tunetx.com